Highlights of the American Academy of Neurology Annual Meeting
Click here to view our current activities in Neurology.
If you didn't make it to New Orleans for the 64th annual meeting of the American Academy of Neurology, it's not too late to catch up on the latest multiple sclerosis (MS) news. In this free CME podcast, MS experts Aaron E. Miller, MD, James D. Bowen, MD, and Stephen Krieger, MD, provide highlights of the meeting, covering updates on MS pathophysiology, immunology, genetics, neuropreservation, testing, imaging, current and emerging disease-modifying therapies, cognitive function, and symptom management. Listen at your convenience to stay current on the latest MS research, and then complete the posttest and evaluation to receive your CME credit.
Aaron E. Miller, MD
- Professor of Neurology and
- Medical Director
- The Corinne Goldsmith
- Dickinson Center for
- Multiple Sclerosis
- Mount Sinai School of Medicine
- New York, NY
James D. Bowen, MD
- Medical Director, Multiple
- Sclerosis Center
- Swedish Neuroscience
- Institute
- Seattle, Washington
Stephen Krieger, MD
- Assistant Professor of Neurology
- The Corinne Goldsmith Dickinson
- Center for Multiple Sclerosis
- Mount Sinai School of Medicine
- New York, NY
James D. Bowen, MD, has received salary/honoraria from Acorda Therapeutics, Inc, Berlex, Bogen Idec, EMS Serono, Inc, Novartis, and Teva Neuroscience; has received consulting fees from Acorda Therapeutics, Inc, Berlex, Inc, Biogen Idec, EMD Serono, Inc, Pfizer Inc, Novartis Pharmaceutical Corporation, and Teva Neuroscience; has contracted research for Acorda Therapeutics, Inc, Avanir Pharmaceuticals, Biogen Idec, Celgene Corporation, DioGenix, EMD Serono, Inc, Genentech, Genzyme Corporation, SmithKline, Medimmune, Novartis Pharmaceutical Corporation, sanofi-aventis, Synthon, UCB Inc, and XenoPort; and has ownership interest in Amgen.
Stephen Krieger, MD, has received honoraria from Bayer HealthCare, Biogen Idec, EMD Serono, Inc, and Teva Neuroscience; and has received consulting fees from Bayer HealthCare, Biogen Idec, Genzyme Corporation, Questcor Pharmaceuticals, and Teva Neuroscience.
Suhayl Dhib-Jalbut, MD, has received consulting fees from Bayer HealthCare, Biogen Idec, Questcor Pharmaceuticals, EMD Serono, Inc, and Teva Neuroscience; and has conducted contracted research for Bayer HealthCare, EMD Serono, Inc, and Teva Neuroscience.
Stephen Krieger, MD, has received honoraria from Bayer HealthCare, Biogen Idec, EMD Serono, Inc, and Teva Neuroscience; and has received consulting fees from Bayer HealthCare, Biogen Idec, Genzyme Corporation, Questcor Pharmaceuticals, and Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP, has received salary/honoraria from Questcor Pharmaceuticals and Teva Neuroscience; has received consulting fees from Avanir Pharmaceuticals, Questcor Pharmaceuticals, and Teva Neuroscience; and has conducted contracted research for Acorda Therapeutics, Biogen Idec, Questcor Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Teva Neuroscience.
Fred D. Lublin, MD, has received salary/honoraria from Bayer HealthCare, Biogen Idec, and Questcor Pharmaceuticals; has received consulting fees from Abbott Laboratories, Acorda Therapeutics, Inc, Actelion, Allozyne, Avanir Pharmaceuticals, Bayer HealthCare, Biogen Idec, Celgene Corporation, Coronado Biosciences, EMD Serono, Genmab, Johnson and Johnson, MediciNova, Inc, MorphoSys, Novartis Pharmaceuticals Corporation, Pfizer Inc, Questcor Pharmaceuticals, Revalesio, Roche Pharmaceuticals, sanofi-aventis, and Teva Neuroscience; and has conducted contracted research for Acorda Therapeutics, Inc, Biogen Idec, Genzyme Corporation, National Institutes of Health, National MS Society, Novartis Pharmaceuticals Corporation, sanofi-aventis, and Teva Neuroscience.
Aaron E. Miller, MD, has conducted contracted research for Acorda Therapeutics, Inc, Biogen Idec, Genentech, Inc, Genzyme, Novartis Pharmaceuticals Corporation, sanofi-aventis, and Teva Neuroscience; has received consulting fees from Acorda Therapeutics, Inc, Biogen Idec, BioMarin, Daiichi-Sankyo, EMD Serono, GlaxoSmithKline, Merck Serono, Novartis Pharmaceuticals Corporation, ONO, sanofi-aventis, and Teva Neuroscience; and is on the speakers bureau for Acorda Therapeutics, Inc, Biogen Idec, EMD Serono, Pfizer, Inc, and Teva Neuroscience.
Available for CME/CE:
Physicians
Publish Date: May 21, 2012 Termination Date: May 20, 2013Nurses
Publish Date: May 21, 2012 Termination Date: May 20, 2013Pharmacists
Publish Date: May 21, 2012 Termination Date: May 20, 2013Estimated time for completion of this activity:
CNE: 1.47 hours
CPE: 1.5 hours
Target Audience
This activity is designed for neurologists and primary care physicians (including family practice, internists, and general practitioners), as well as nurses and pharmacists, who manage and treat patients with multiple sclerosis.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for diagnosing, treating, and managing patients with multiple sclerosis.
Learning Objective (s)
- Assess emerging data on MS pathophysiology, immunology, genetics, and neuropreservation in order to better understand the impact of the disease and the mechanisms of disease-modifying treatments.
- Evaluate the prognostic value of emerging biomarkers and imaging correlates for MS in predicting long-term outcomes and treatment response.
- Appraise recent data on clinical and radiologic predictors of MS-related cognitive dysfunction in order to better recognize at-risk patients.
- Analyze recent efficacy and safety data of current and emerging MS therapies in order to make informed treatment decisions that improve patient outcomes.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 1.47 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This podcast series is worth up to 1.5 contact hour (0.15 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-12-1157-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Aaron E. Miller, MD has conducted contracted research for Acorda Therapeutics, Biogen Idec, Genentech, Inc, Genzyme, Novartis Pharmaceuticals Corporation, Sanofi-aventis, and Teva Neuroscience; has received consulting fees from Acorda Therapeutics, Biogen Idec, BioMarin, Daiichi Sankyo, EMD Serono, GlaxoSmithKline, Merck Serono, Novartis Pharmaceuticals Corporation, ONO, Sanofi-aventis, and Teva Neuroscience; and is on the speakers bureau for Acorda Therapeutics, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
James D. Bowen, MD has received salary/honoraria from Acorda Therapeutics, Inc, Berlex, Bogen Idec, EMS Serono, Inc, Novartis, and Teva Neuroscience; has received consulting fees from Acorda Therapeutics, Inc, Berlex, Inc, Biogen Idec, EMD Serono, Inc, Pfizer Inc, Novartis Pharmaceutical Corporation, and Teva Neuroscience; has contracted research for Acorda Therapeutics, Inc, Avanir Pharmaceuticals, Biogen Idec, Celgene Corporation, DioGenix, EMD Serono, Inc, Genentech, Genzyme Corporation, SmithKline, Medimmune, Novartis Pharmaceutical Corporation, sanofi-aventis, Synthon, UCB Inc, and XenoPort; and has ownership interest in Amgen.
Stephen Krieger, MD has received honoraria from Bayer HealthCare, Biogen Idec, EMD Serono, Inc, and Teva Neuroscience; and has received consulting fees from Bayer HealthCare, Biogen Idec, Genzyme Corporation, Questcor Pharmaceuticals, and Teva Neuroscience.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Lauren A. Cerruto has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Anne H. Cross, MD has received salary/honoraria from CMEducation Resources LLC, DIME, WebMD, and Teva Neuroscience; has received consulting fees from Bayer HealthCare, Biogen Idec, Coronado Biosciences, Hoffmann-LaRoche, sanofi-aventis, and Teva Neuroscience; and has received fees for non-CME services from Gerson Lehrman Group, and Guidepoint Global LLC; has conducted contracted research for sanofi-aventis and Roche Pharmaceuticals.
Suhayl Dhib-Jalbut, MD has received consulting fees from Bayer HealthCare, Biogen Idec, Questcor Pharmaceuticals, EMD Serono, Inc, and Teva Neuroscience; and has conducted contracted research for Bayer HealthCare, EMD Serono, Inc, and Teva Neuroscience.
Stephen Krieger, MD has received honoraria from Bayer HealthCare, Biogen Idec, EMD Serono, Inc, and Teva Neuroscience; and has received consulting fees from Bayer HealthCare, Biogen Idec, Genzyme Corporation, Questcor Pharmaceuticals, and Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP has received salary/honoraria from Questcor Pharmaceuticals and Teva Neuroscience; has received consulting fees from Avanir Pharmaceuticals, Questcor Pharmaceuticals, and Teva Neuroscience; and has conducted contracted research for Acorda Therapeutics, Biogen Idec, Questcor Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Teva Neuroscience.
Fred D. Lublin, MD has received salary/honoraria from Bayer HealthCare, Biogen Idec, and Questcor Pharmaceuticals; has received consulting fees from Abbott Laboratories, Acorda Therapeutics, Inc, Actelion, Allozyne, Avanir Pharmaceuticals, Bayer HealthCare, Biogen Idec, Celgene Corporation, Coronado Biosciences, EMD Serono, Genmab, Johnson and Johnson, MediciNova, Inc, MorphoSys, Novartis Pharmaceuticals Corporation, Pfizer Inc, Questcor Pharmaceuticals, Revalesio, Roche Pharmaceuticals, sanofi-aventis, and Teva Neuroscience; and has conducted contracted research for Acorda Therapeutics, Inc, Biogen Idec, Genzyme Corporation, National Institutes of Health, National MS Society, Novartis Pharmaceuticals Corporation, sanofi-aventis, and Teva Neuroscience.
Aaron E. Miller, MD has conducted contracted research for Acorda Therapeutics, Inc, Biogen Idec, Genentech, Inc, Genzyme, Novartis Pharmaceuticals Corporation, sanofi-aventis, and Teva Neuroscience; has received consulting fees from Acorda Therapeutics, Inc, Biogen Idec, BioMarin, Daiichi-Sankyo, EMD Serono, GlaxoSmithKline, Merck Serono, Novartis Pharmaceuticals Corporation, ONO, sanofi-aventis, and Teva Neuroscience; and is on the speakers bureau for Acorda Therapeutics, Inc, Biogen Idec, EMD Serono, Pfizer, Inc, and Teva Neuroscience.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: May 21, 2012 Termination Date: May 20, 2013Nurses
Publish Date: May 21, 2012 Termination Date: May 20, 2013Pharmacists
Publish Date: May 21, 2012 Termination Date: May 20, 2013Estimated time for completion of this activity:
CNE: 1.47 hours
CPE: 1.5 hours
Target Audience
This activity is designed for neurologists and primary care physicians (including family practice, internists, and general practitioners), as well as nurses and pharmacists, who manage and treat patients with multiple sclerosis.
Activity Goal
The goal of this CME/CE activity is to examine current and emerging strategies for diagnosing, treating, and managing patients with multiple sclerosis.
Learning Objective (s)
- Assess emerging data on MS pathophysiology, immunology, genetics, and neuropreservation in order to better understand the impact of the disease and the mechanisms of disease-modifying treatments.
- Evaluate the prognostic value of emerging biomarkers and imaging correlates for MS in predicting long-term outcomes and treatment response.
- Appraise recent data on clinical and radiologic predictors of MS-related cognitive dysfunction in order to better recognize at-risk patients.
- Analyze recent efficacy and safety data of current and emerging MS therapies in order to make informed treatment decisions that improve patient outcomes.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.
Upon completion of this course, participants will be awarded 1.47 nursing contact hour(s).
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This podcast series is worth up to 1.5 contact hour (0.15 CEU). The ACPE Universal Activity Number assigned to this Knowledge-type activity is 0052-0000-12-1157-H01-P.
Pharmacists should only claim credit commensurate with the extent of their participation in the activity.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Aaron E. Miller, MD has conducted contracted research for Acorda Therapeutics, Biogen Idec, Genentech, Inc, Genzyme, Novartis Pharmaceuticals Corporation, Sanofi-aventis, and Teva Neuroscience; has received consulting fees from Acorda Therapeutics, Biogen Idec, BioMarin, Daiichi Sankyo, EMD Serono, GlaxoSmithKline, Merck Serono, Novartis Pharmaceuticals Corporation, ONO, Sanofi-aventis, and Teva Neuroscience; and is on the speakers bureau for Acorda Therapeutics, Biogen Idec, EMD Serono, Pfizer Inc, and Teva Neuroscience.
James D. Bowen, MD has received salary/honoraria from Acorda Therapeutics, Inc, Berlex, Bogen Idec, EMS Serono, Inc, Novartis, and Teva Neuroscience; has received consulting fees from Acorda Therapeutics, Inc, Berlex, Inc, Biogen Idec, EMD Serono, Inc, Pfizer Inc, Novartis Pharmaceutical Corporation, and Teva Neuroscience; has contracted research for Acorda Therapeutics, Inc, Avanir Pharmaceuticals, Biogen Idec, Celgene Corporation, DioGenix, EMD Serono, Inc, Genentech, Genzyme Corporation, SmithKline, Medimmune, Novartis Pharmaceutical Corporation, sanofi-aventis, Synthon, UCB Inc, and XenoPort; and has ownership interest in Amgen.
Stephen Krieger, MD has received honoraria from Bayer HealthCare, Biogen Idec, EMD Serono, Inc, and Teva Neuroscience; and has received consulting fees from Bayer HealthCare, Biogen Idec, Genzyme Corporation, Questcor Pharmaceuticals, and Teva Neuroscience.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Lauren A. Cerruto has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Anne H. Cross, MD has received salary/honoraria from CMEducation Resources LLC, DIME, WebMD, and Teva Neuroscience; has received consulting fees from Bayer HealthCare, Biogen Idec, Coronado Biosciences, Hoffmann-LaRoche, sanofi-aventis, and Teva Neuroscience; and has received fees for non-CME services from Gerson Lehrman Group, and Guidepoint Global LLC; has conducted contracted research for sanofi-aventis and Roche Pharmaceuticals.
Suhayl Dhib-Jalbut, MD has received consulting fees from Bayer HealthCare, Biogen Idec, Questcor Pharmaceuticals, EMD Serono, Inc, and Teva Neuroscience; and has conducted contracted research for Bayer HealthCare, EMD Serono, Inc, and Teva Neuroscience.
Stephen Krieger, MD has received honoraria from Bayer HealthCare, Biogen Idec, EMD Serono, Inc, and Teva Neuroscience; and has received consulting fees from Bayer HealthCare, Biogen Idec, Genzyme Corporation, Questcor Pharmaceuticals, and Teva Neuroscience.
Robert P. Lisak, MD, FAAN, FRCP has received salary/honoraria from Questcor Pharmaceuticals and Teva Neuroscience; has received consulting fees from Avanir Pharmaceuticals, Questcor Pharmaceuticals, and Teva Neuroscience; and has conducted contracted research for Acorda Therapeutics, Biogen Idec, Questcor Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Teva Neuroscience.
Fred D. Lublin, MD has received salary/honoraria from Bayer HealthCare, Biogen Idec, and Questcor Pharmaceuticals; has received consulting fees from Abbott Laboratories, Acorda Therapeutics, Inc, Actelion, Allozyne, Avanir Pharmaceuticals, Bayer HealthCare, Biogen Idec, Celgene Corporation, Coronado Biosciences, EMD Serono, Genmab, Johnson and Johnson, MediciNova, Inc, MorphoSys, Novartis Pharmaceuticals Corporation, Pfizer Inc, Questcor Pharmaceuticals, Revalesio, Roche Pharmaceuticals, sanofi-aventis, and Teva Neuroscience; and has conducted contracted research for Acorda Therapeutics, Inc, Biogen Idec, Genzyme Corporation, National Institutes of Health, National MS Society, Novartis Pharmaceuticals Corporation, sanofi-aventis, and Teva Neuroscience.
Aaron E. Miller, MD has conducted contracted research for Acorda Therapeutics, Inc, Biogen Idec, Genentech, Inc, Genzyme, Novartis Pharmaceuticals Corporation, sanofi-aventis, and Teva Neuroscience; has received consulting fees from Acorda Therapeutics, Inc, Biogen Idec, BioMarin, Daiichi-Sankyo, EMD Serono, GlaxoSmithKline, Merck Serono, Novartis Pharmaceuticals Corporation, ONO, sanofi-aventis, and Teva Neuroscience; and is on the speakers bureau for Acorda Therapeutics, Inc, Biogen Idec, EMD Serono, Pfizer, Inc, and Teva Neuroscience.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|
The American Academy of Neurology held its 64th annual meeting April 21 through April 28, 2012, in New Orleans, Louisiana. In this podcast, multiple sclerosis (MS) experts Aaron E. Miller, MD, James D. Bowen, MD, and Stephen Krieger, MD, discuss the meetings most noteworthy MS presentations. Pathophysiology, Immunology, Genetics, and Neuropreservation
Testing and Imaging
Update on Current MS Therapies
Update on Emerging MS Therapies
MS-Related Cognitive Dysfunction
MS Symptom Management
|



